Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients

INTRODUCTION: No data are provided about the effect of triple combination therapy with Lopinavir/Ritonavir (LPN/RTN), hydroxychloroquine (HQ) and azithromycin (AZT) on corrected QT (QTc) interval and arrhythmic risk, in COVID-19 patients. This study aims to describe the incidence of extreme QTc inte...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Pharmacol
Auteurs principaux: Russo, Vincenzo, Carbone, Andreina, Mottola, Filiberto Fausto, Mocerino, Rosa, Verde, Raffaele, Attena, Emilio, Verde, Nicoletta, Di Micco, Pierpaolo, Nunziata, Luigi, Santelli, Francesco, Nigro, Gerardo, Severino, Sergio
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2020
Sujets:
Pharmacology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7578422/
https://ncbi.nlm.nih.gov/pubmed/33132915
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.582348
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires